Description
Moderiba (Ribavirin USP) 600mg/600mg Online
Moderiba (Ribavirin USP) is used in combination with injectable interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b to treat chronic hepatitis C infection. The combination of Moderiba and peginterferon alfa-2b is used to treat adults and children 3 years of age and older who show symptoms of liver damage. Moderiba is an antiviral agent that treats hepatitis C virus.
Moderiba is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with Moderiba.
The vast majority of infants and children with RSV infection have a disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Moderiba (Moderiba) aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Moderiba (Moderiba) should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.
